Spectral Medical Inc T.EDT

Alternate Symbol(s): EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.

TSX:EDT - Post by User

Spectral Medical Inc

Bullboard Posts

Post by overthelakeonlyon Apr 01, 2016 9:19am

126 Views

Post# 24719034

PATIENTS RANDOMIZED

In their March 29, 2016 Management's discussion and analysis, we can read '' The company is now on track to recruit the last 22 of the required 446 evaluable trial patients. On March 1st, it was 30. So it's 8 patients in 28 days. following these results, the trial should be finish around June 15, 2016

Bullboard Posts

NervGen Pharma: Proof that NVG-291 works?